MRNA 下跌5.5%，起因是后期癌症疫苗阳性数据泄露（相较单用 Keytruda，复发/死亡风险相对降低42%）——这并非糟糕的结果。分析师认为这是“买传闻、卖新闻”：该股一年内上涨600%，已提前计入突破性进展，因此此次下跌看起来像是在官方三期结果公布前的获利了结。
逐段跳播
Diane King Hall和我一起来看Moderna。我们昨天稍微谈过这个。昨天出现了一轮剧烈而戏剧性的抛售。
Diane King Hall is joining me to take a look at Moderna . We talked a little about this yesterday. It was an intense and dramatic sell-off yesterday.
昨天，这导致市值减少了240亿美元。Moderna今天仍面临压力。但这并不意味着业绩很差。这些压力出现在有关癌症疫苗试验的一些信息被泄露之后。我们原本预计它会在本周末发布。它仍计划在本周末发布。
Yesterday, this resulted in a $24 billion reduction in market value. There is ongoing pressure on Moderna today. But that doesn't mean the results were bad. These pressures come after some information regarding cancer vaccine trials was leaked .
We were expecting it to be released at the end of this week. It is still scheduled to be released at the end of this week.
Moderna股价下跌了约5.5%。分析师们说的是，这看起来像是典型的“买传闻、卖新闻”。积极的临床结果仍可能让投资者感到困惑，因为股价已经提前反映了重大突破。这解释了我们所经历的部分压力。
Moderna's shares fell by about 5.5 percent. What analysts are saying is that this looks like a classic case of "buy on the rumor, sell on the news". Positive clinical results are still able to confuse investors, because the stock had already factored in a major breakthrough.
This explains some of the pressures we have experienced.
这项研究处于后期阶段，纳入了1000多名高危皮肤癌患者。关于我们从泄露信息中看到的内容，据报道，与单用Keytruda相比，它将癌症复发或死亡的风险降低了42%。它还将癌症扩散到身体其他部位的风险降低了38%。
接受联合疗法的患者中有82%保持存活且癌症未复发。与单用Keytruda相比，这是更好的差异。
The study, in its later stages, included more than 1,000 patients with high-risk skin cancer. Regarding what we see from leaks, according to reports, it reduced the risk of cancer recurrence or death by 42% compared to using Keytruda alone.
It also reduced the risk of cancer spreading to other parts of the body by 38%. 82% of patients who received the combined therapy remained alive without the cancer returning. This is a better difference compared to using Keytruda alone.
42%这个数字代表的是风险的相对下降，而不是提高了42个百分点。因此，从分析师的角度看，股票被卖出是因为，我们又一次已经看到了第一和第二阶段的积极结果。我们在等待第三阶段。我们将在本周末正式收到第三阶段的结果。
浮现出来的是，它在减少癌症和防止复发方面有所改善，但在那些试验结果公布之前，股价已经大幅上涨了，Nicole。
The figure of 42% represents a relative decrease in risk, not an improvement of 42 percentage points. Therefore, from the analysts' point of view, the sale of the stock occurred because, once again, we had already seen positive results from the first and second phases.
We are waiting for the third phase. We will officially receive the results of the third phase at the end of this week. What emerged was that it was an improvement in terms of reducing cancer and preventing its recurrence, but the stock had already risen significantly before the results of those trials came out , Nicole.
是的，也许那只是获利了结，不是吗？这只股票一年内涨了600%，夏天出现向上跳空缺口并继续上涨。所以，有时候人们买传闻、卖新闻，而且确实有一些获利了结。
Yes, perhaps that was just profit-making, was n't it? The stock has risen 600% in one year, experienced an upward gap during the summer and continued to rise. So, sometimes people buy based on rumors and sell based on news, and there was certainly some profit-taking.
观察点
这个频道对 $MRNA 的历次判断
Schwab Network 在这只股票上共 3 条判断，这里只列相邻的几条。